Compare AMWL & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMWL | ELDN |
|---|---|---|
| Founded | 2006 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 111.4M | 123.1M |
| IPO Year | 2020 | N/A |
| Metric | AMWL | ELDN |
|---|---|---|
| Price | $4.62 | $2.21 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 2 |
| Target Price | $7.58 | ★ $8.50 |
| AVG Volume (30 Days) | 88.7K | ★ 885.6K |
| Earning Date | 02-11-2026 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $265,023,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 4.33 | N/A |
| 52 Week Low | $3.71 | $1.35 |
| 52 Week High | $12.95 | $4.97 |
| Indicator | AMWL | ELDN |
|---|---|---|
| Relative Strength Index (RSI) | 44.97 | 73.04 |
| Support Level | $4.64 | $1.70 |
| Resistance Level | $5.29 | $1.76 |
| Average True Range (ATR) | 0.31 | 0.12 |
| MACD | -0.05 | 0.08 |
| Stochastic Oscillator | 5.00 | 93.83 |
American Well Corp is a telehealth company enabling digital delivery of care for its customers. Its platform, Amwell, digital care delivery solution that equips health systems, health plans, government, and innovator clients with the tools to enable new models of care for their patients and members enabling care delivery across the full healthcare continuum - from primary and urgent care in the home to high acuity specialty consults, such as telestroke and telepsychiatry, in the hospital. It provides both on-demand and scheduled consultations. Its Health Plan Programs include Virtual Primary Care, Musculoskeletal Care, Dermatology Care, and Chronic Care among others.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.